Physician profile
Eric C South
NPI 1093940199
$2,089.17
in general payments reported to CMS, 2019-2025
14 companies · $921 in 2025
The $921 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.96 · 2020: $19.49 · 2022: $163 · 2023: $224 · 2024: $662 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $386.12 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $343.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $255.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $241.79 | 2022-2023 | |
| Amgen INC. | $200.52 | 2024-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $171.91 | 2020-2025 | |
| Exact Sciences Corporation | $154.75 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $134.02 | 2024-2025 | Sunosi |
| Solventum Corporation | $87.80 | 2025 | Activ.A.C. |
| Supernus Pharmaceuticals, INC. | $30.70 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $29.74 | 2024 | Trintellix |
| Dexcom, INC. | $21.13 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $17.37 | 2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $14.54 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric South listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.